Polpharma SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Polpharma SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013194
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ポーランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Polpharma SA (Polpharma) undertakes the research, manufacture and marketing of generic drugs, prescription drugs and over the counter medications. It provides drugs in cardiology, gastroenterology and neurology areas. The company also manufactures over the counter (OTC) medications, dietary supplements, cosmetic products, medical devices and phyto-pharmaceuticals as well as active pharmaceutical ingredients (APIs). Polpharma has seven manufacturing plants in Russia, Poland and Kazakhstan. The company operates in Central and Eastern Europe, the Caucasus and Central Asia markets. Polpharma group includes Santo, Medana SA, Akrikhin Pharmaceuticals, Polfa Warszawa S.A. Polpharma is headquartered in Starogard Gdanski, Poland.

Polpharma SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Polpharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Polpharma SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Polpharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Polpharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Polpharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Polpharma SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Polpharma Enters into Agreement with Epirus Biopharma 10
Debt Offering 11
Khimfarm Plans Public Offering Of Senior Notes For US$66 Million 11
Asset Transactions 12
Pfizer Completes Acquisition Of Polocard From Polpharma For US$32 Million 12
Aflofarm Plans To Acquire Polocard From Polpharma 13
Acquisition 14
Polpharma to Acquire EPIRUS Netherlands from EPIRUS Biopharma 14
Polpharma Completes Acquisition Of 85.14% Stake In Polfa Warszawa For US$249 Million 16
Polpharma Acquires Kazakhstan Drug Maker Khimfarm 18
Polpharma Acquires 77% Stake In Cenovapharma 19
Polpharma SA – Key Competitors 20
Polpharma SA – Key Employees 21
Polpharma SA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Polpharma SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Polpharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Polpharma SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Polpharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Polpharma SA, Deals By Therapy Area, 2011 to YTD 2017 8
Polpharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Polpharma Enters into Agreement with Epirus Biopharma 10
Khimfarm Plans Public Offering Of Senior Notes For US$66 Million 11
Pfizer Completes Acquisition Of Polocard From Polpharma For US$32 Million 12
Aflofarm Plans To Acquire Polocard From Polpharma 13
Polpharma to Acquire EPIRUS Netherlands from EPIRUS Biopharma 14
Polpharma Completes Acquisition Of 85.14% Stake In Polfa Warszawa For US$249 Million 16
Polpharma Acquires Kazakhstan Drug Maker Khimfarm 18
Polpharma Acquires 77% Stake In Cenovapharma 19
Polpharma SA, Key Competitors 20
Polpharma SA, Key Employees 21
Polpharma SA, Other Locations 22
Polpharma SA, Subsidiaries 23

★海外企業調査レポート[Polpharma SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Carmell Therapeutics Corp:製品パイプライン分析
    Summary Carmell Therapeutics Corp (Carmell) is a biotechnology company that develops and commercializes bone healing accelerants and tissue healing accelerants. Its pipeline portfolio encompasses adjunctive treatment for long bone fractures in Phase I and Phase II a; and adjunctive treatment for tot …
  • ProteoMediX AG:製品パイプライン分析
    Summary ProteoMediX AG (ProteoMediX) is a medical diagnostic company which identifies and develops novel biomarkers for the early detection of cancer and the personalized treatment. The company develops non-invasive diagnostic tests for the detection, prognosis, stratification, and therapy-selection …
  • Hepion Pharmaceuticals Inc (HEPA):企業の財務・戦略的SWOT分析
    Summary Hepion Pharmaceuticals Inc (Hepion) formerly known as ContraVir Pharmaceuticals Inc, is a biopharmaceutical company that offers development and commercialization of targeted antiviral therapies. The company provides pipeline product such as TXL, potent prodrug of antiviral tenofovir and CRV4 …
  • Tata Consultancy Services Limited:企業の戦略・SWOT・財務情報
    Tata Consultancy Services Limited - Strategy, SWOT and Corporate Finance Report Summary Tata Consultancy Services Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Foster Electric Co Ltd:企業の戦略・SWOT・財務情報
    Foster Electric Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Foster Electric Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Southern California Edison Co:企業の発電所・SWOT分析2018
    Southern California Edison Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Sherritt International Corp (S):石油・ガス:M&Aディール及び事業提携情報
    Summary Sherritt International Corp (Sherritt) is a natural resources company. It carries out mining and refining activities for the production of nickel and cobalt from lateritic ores with ownership stake in Moa Joint Venture and Ambatovy Joint Venture. The company also explores, develops and produ …
  • New York Power Authority:発電所・企業SWOT分析
    New York Power Authority - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • GFT Technologies AG (GFT):企業の財務・戦略的SWOT分析
    Summary GFT Technologies AG (GFT Technologies) is a technology company that implements, develops, and maintains information technology solutions. The company’s services comprise application management, bespoke development, product based implementation, and business and IT consultation services. It a …
  • Illovo Sugar Africa Pty Ltd:企業の戦略的SWOT分析
    Illovo Sugar Africa Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Owens & Minor Inc (OMI):医療機器:M&Aディール及び事業提携情報
    Summary Owens & Minor Inc (Owens & Minor) is a healthcare services company, which provides supply chain services to healthcare providers and manufacturers of healthcare products. It provides logistics services for disposable medical supplies, devices and implants. Owens & Minor offers medical and su …
  • Ypsomed Holding AG (YPSN):企業の製品パイプライン分析
    Summary Ypsomed Holding AG (Ypsomed) is a medical device company that designs, develops and manufactures injection and infusion systems for self-medication and offers related services. It offers autoinjectors, dual chamber pens, and pen injectors. The company also offers services ranging from design …
  • Antisense Therapeutics Ltd (ANP):製薬・医療:M&Aディール及び事業提携情報
    Summary Antisense Therapeutics Ltd (Antisense Therapeutics) is clinical staged biopharmaceutical company which focuses on the discovery, development and commercialization of second generation antisense pharmaceuticals for various medical conditions that have large unmet medical needs. It focuses on …
  • Curetis NV (CURE):企業の財務・戦略的SWOT分析
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company provides diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for cartridges, diseases such as implant and tissue inf …
  • Grupo Aeroportuario del Centro Norte SAB de CV:企業の戦略・SWOT・財務情報
    Grupo Aeroportuario del Centro Norte SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Grupo Aeroportuario del Centro Norte SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • GeNeuro SA (GNRO):企業の財務・戦略的SWOT分析
    Summary GeNeuro SA (GeNeuro) is a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflammatory and degenerative disorders associated with endogenous retroviruses. GeNeuro develops therap …
  • IncellDx Inc:医療機器:M&Aディール及び事業提携情報
    Summary IncellDx Inc (IncellDx) is a single cell diagnostic company that develops transformative diagnostic and prognostic clinical patient information technologies. The company detects and monitors life threatening viral diseases in the areas of cervical cancer, HIV and AIDS, hepatitis, and organ t …
  • Grand Gulf Energy Ltd (GGE):石油・ガス:M&Aディール及び事業提携情報
    Summary Grand Gulf Energy Ltd (Grand Gulf Energy), formerly Alto Energy International Ltd, is an oil and gas exploration and production company. The company acquires, explores and develops conventional oil and gas assets in the US oil and gas basins. It holds interests in Napoleonville Salt Dome pro …
  • Kuraray Co., Ltd.:企業の戦略・SWOT・財務分析
    Kuraray Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kuraray Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Mayo Clinic:製薬・医療:M&Aディール及び事業提携情報
    Summary Mayo Clinic (Mayo) is a not-for-profit medical practice and medical research organization. It provides comprehensive medical facilities and programs related to patient care services, research and medical education. It offers specialized medical care with medical departments and centers in mo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆